FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199359007> ?p ?o ?g. }

• W3199359007 abstract "Abstract Background lncRNA-CDKN2B antisense RNA 1 (ANRIL) and SRY-box transcription factor 9 (SOX9) has abnormal expression in many tumors including glioma, but the underlying molecular mechanism is unclear. This study set out to investigate the serum lncRNA-ANRIL and SOX9 levels in glioma patients and their effects on prognosis. Methods We enrolled 142 glioma patients admitted to our hospital from May 2014 to May 2016 into the research group (RG) and 120 healthy subjects receiving concurrent physical examinations into the control group (CG). Fasting peripheral blood (4 mL each) wa s sampled from subjects from the two groups. Using the quantitative real-time polymerase chain reaction (qRT-PCR), lncRNA-ANRIL and SOX9 were measured to explore their values in the early diagnosis of glioma. Patients from RG were followed up for 3 years to analyze the influence of lncRNA-ANRIL and SOX9 on patient prognosis. We purchased glioma cell lines U251 and U87 and grouped them according to the transfection of different plasmids. We conducted CCK8 assay to test cell proliferation, Transwell assay to test cell invasion, the flow cytometry to test cell apoptosis, and Western Blot assay to measure bcl-2 and bax protein levels. Results ANRIL and SOX9 were evidently higher in RG than in CG ( P <0.01). The receiver operating characteristic (ROC) curve revealed that the diagnostic sensitivity of ANRIL combined with SOX9 for glioma was 81.62%, and the specificity was 90.83% ( P <0.01). ANRIL and SOX9 were closely related to tumor grade, tumor diameter, distant metastasis, and family history of glioma ( P <0.01). In total, 135 patients were successfully followed up (95.07%). Patients with high levels of ANRIL and SOX9 had a markedly poorer prognosis than those with low levels ( P <0.05). ANRIL and SOX9 were markedly higher in glioma cell lines (U251 and U87) than in normal brain cells ( P <0.01). The proliferation and invasion of U251 cells were notably reduced after the transfection of ANRIL and SOX9 inhibitory sequences ( P <0.01), but the apoptosis was notably increased ( P <0.01). Bcl-2 expression was markedly increased in lncRNA-ANRIL-inhibitor and SOX9-inhibitor ( P <0.01), while bax expression was markedly reduced in lncRNA-ANRIL-inhibitor and SOX9-inhibitor ( P <0.01). Conclusion lncRNA-ANRIL and SOX9 levels were higher in glioma patients than in healthy people. High-lncRNA-ANRIL and SOX9 levels were strongly associated with unfavorable prognosis of patients. The testing of biological behaviors revealed that lncRNA-ANRIL and SOX9 worked as tumor-promoting genes in glioma." @default.
• W3199359007 created "2021-09-27" @default.
• W3199359007 creator A5008455144 @default.
• W3199359007 creator A5021149979 @default.
• W3199359007 creator A5049817947 @default.
• W3199359007 date "2021-09-23" @default.
• W3199359007 modified "2023-10-15" @default.
• W3199359007 title "Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis" @default.
• W3199359007 cites W1623601970 @default.
• W3199359007 cites W1969880510 @default.
• W3199359007 cites W2012150747 @default.
• W3199359007 cites W2025917129 @default.
• W3199359007 cites W2027807256 @default.
• W3199359007 cites W2049621625 @default.
• W3199359007 cites W2065646079 @default.
• W3199359007 cites W2086668210 @default.
• W3199359007 cites W2099001954 @default.
• W3199359007 cites W2113122028 @default.
• W3199359007 cites W2135465849 @default.
• W3199359007 cites W2150988914 @default.
• W3199359007 cites W2207064026 @default.
• W3199359007 cites W2224717864 @default.
• W3199359007 cites W2278061057 @default.
• W3199359007 cites W2313086999 @default.
• W3199359007 cites W2345877254 @default.
• W3199359007 cites W2386703324 @default.
• W3199359007 cites W2411895718 @default.
• W3199359007 cites W2472102520 @default.
• W3199359007 cites W2512804330 @default.
• W3199359007 cites W2570696586 @default.
• W3199359007 cites W2589879570 @default.
• W3199359007 cites W2607640564 @default.
• W3199359007 cites W2747530765 @default.
• W3199359007 cites W2751069891 @default.
• W3199359007 cites W2765722748 @default.
• W3199359007 cites W2767886606 @default.
• W3199359007 cites W2770043250 @default.
• W3199359007 cites W2799819879 @default.
• W3199359007 cites W2800282544 @default.
• W3199359007 cites W2810776516 @default.
• W3199359007 cites W2888315207 @default.
• W3199359007 cites W2951880440 @default.
• W3199359007 cites W2995471545 @default.
• W3199359007 cites W3039024239 @default.
• W3199359007 cites W3043583468 @default.
• W3199359007 cites W3134284631 @default.
• W3199359007 cites W3152752780 @default.
• W3199359007 cites W4211105004 @default.
• W3199359007 doi "https://doi.org/10.1186/s12957-021-02392-2" @default.
• W3199359007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8461887" @default.
• W3199359007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34556140" @default.
• W3199359007 hasPublicationYear "2021" @default.
• W3199359007 type Work @default.
• W3199359007 sameAs 3199359007 @default.
• W3199359007 citedByCount "12" @default.
• W3199359007 countsByYear W31993590072022 @default.
• W3199359007 countsByYear W31993590072023 @default.
• W3199359007 crossrefType "journal-article" @default.
• W3199359007 hasAuthorship W3199359007A5008455144 @default.
• W3199359007 hasAuthorship W3199359007A5021149979 @default.
• W3199359007 hasAuthorship W3199359007A5049817947 @default.
• W3199359007 hasBestOaLocation W31993590071 @default.
• W3199359007 hasConcept C104317684 @default.
• W3199359007 hasConcept C105580179 @default.
• W3199359007 hasConcept C126322002 @default.
• W3199359007 hasConcept C143998085 @default.
• W3199359007 hasConcept C190283241 @default.
• W3199359007 hasConcept C203014093 @default.
• W3199359007 hasConcept C2778227246 @default.
• W3199359007 hasConcept C2780140570 @default.
• W3199359007 hasConcept C4692481 @default.
• W3199359007 hasConcept C48023723 @default.
• W3199359007 hasConcept C502942594 @default.
• W3199359007 hasConcept C553184892 @default.
• W3199359007 hasConcept C55493867 @default.
• W3199359007 hasConcept C71924100 @default.
• W3199359007 hasConcept C86803240 @default.
• W3199359007 hasConceptScore W3199359007C104317684 @default.
• W3199359007 hasConceptScore W3199359007C105580179 @default.
• W3199359007 hasConceptScore W3199359007C126322002 @default.
• W3199359007 hasConceptScore W3199359007C143998085 @default.
• W3199359007 hasConceptScore W3199359007C190283241 @default.
• W3199359007 hasConceptScore W3199359007C203014093 @default.
• W3199359007 hasConceptScore W3199359007C2778227246 @default.
• W3199359007 hasConceptScore W3199359007C2780140570 @default.
• W3199359007 hasConceptScore W3199359007C4692481 @default.
• W3199359007 hasConceptScore W3199359007C48023723 @default.
• W3199359007 hasConceptScore W3199359007C502942594 @default.
• W3199359007 hasConceptScore W3199359007C553184892 @default.
• W3199359007 hasConceptScore W3199359007C55493867 @default.
• W3199359007 hasConceptScore W3199359007C71924100 @default.
• W3199359007 hasConceptScore W3199359007C86803240 @default.
• W3199359007 hasIssue "1" @default.
• W3199359007 hasLocation W31993590071 @default.
• W3199359007 hasLocation W31993590072 @default.
• W3199359007 hasLocation W31993590073 @default.
• W3199359007 hasLocation W31993590074 @default.
• W3199359007 hasOpenAccess W3199359007 @default.
• W3199359007 hasPrimaryLocation W31993590071 @default.
• W3199359007 hasRelatedWork W1512954123 @default.

• next